Abstract:
Methods and compositions are disclosed uitlizing the optically pure (2S, 4R) isomer of itraconazole. This compound is a potent drug for the treatment of local and systemic fungal, yeast, and dermatophyte infections, while avoiding the concomitant liability of adverse effects associated with the racemic mixture of itraconazole.
Abstract:
Liposomal-encapsulated taxol or an antineoplastic derivative thereof or a mixture thereof is provided which is used to effect a therapeutically enhanced method of treating cancer, and which may be used advantageously in combination with hyperthermia. The liposomes confer enhanced stability and solubility to taxol or derivatives thereof.
Abstract:
An antibody which is immunoreactive against mammary-derived growth factor 1 (MDGF1) and related growth factors. A new growth factor/growth factor receptor-oncogene family. New therapeutic agents based on this system for treatment of disease.
Abstract:
A method for detecting MDGF1 as a diagnostic or prognostic variable for breast cancer or other disease in a mammal, which comprises: a) contacting a portion of a tissue sample or body fluid from the mammal with one or more antibodies directed against MDGF1, and detecting the presence of MDGF1 by a quantitative assay, or b) detecting functional receptors in tissue membrane fractions by ligand binding and by determining phosphotyrosine accumulation on a specific protein, or both.
Abstract:
A method for inhibiting the growth of adenocarcinoma cells in a human, which cells overexpress the oncogene erbB-2, which entails administering to said human an amount of a 30 Kd glycoprotein effective to inhibit the growth of said cells.
Abstract:
A method of evaluating tissue changes in a mammal occurring durint therapeutic hyperthermia, comprising: a) applying therapeutic hyperthermia to said mammal and monitoring the changes in tissue electrical impendance before, during and after said therapeutic hyperthermia, or any combination thereof, and b) determining the extent of tissue change in said mammal from the changes in tissue electrical impedance.
Abstract:
Site-specific heterobifunctional crosslinkers of the formula: X-COCH(NH2)-Y-Z, where X is a carbonyl reactive group, Y is a variable length spacer, and Z is a thiol reactive group, are useful for the specific labelling of biomolecules or bioaffecting molecules.
Abstract:
A composition made up of a liposome-encapsulated vinca alkaloid and the method for using a liposome-encapsulated vinca alkaloid to treat tumors is disclosed. This composition possesses an antitumor activity and a lower toxicity as compared to nonencapsulated drug.
Abstract:
Compounds of formula (I), wherein each of R1 and R2 is independently selected from the group consisting of halogen, hydroxy, or mono carboxylic acid or R1 and R2 together is a multifunctional carboxylic acid residue which forms a ring with the platinum atom through two oxygens of said multifunctional carboxylic acid; and R3 is a deoxy mono or disaccharide or a derivative thereof; and R4 is selected from the group consisting of hydrogen, C1-4-alkyl, phenyl, benzyl, substituted phenyl or substituted benzyl, wherein substituents are selected from the group consisting of halogen, nitro, C1-2-alkoxy, carboxy, carbonyl ester or phenyl or a pharmaceutically acceptable salt thereof are disclosed. Compositions containing these compounds and methods using these compounds are also discussed.